Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

Please provide your email address to receive an email when new articles are posted on . Although rituximab was safe and well tolerated in acetylcholine receptor antibody-positive generalized ...

Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) ...

Decisions may depend on thymoma and what type of auto-antibodies are present ...

Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody ...

For several decades, thymectomy has been an option for the treatment of myasthenia gravis, a rare, long-term, autoimmune neuromuscular disease. This randomized clinical trial, carried out in 67 ...

BUFFALO, N.Y. -- A new study in the New England Journal of Medicine addresses a question doctors have sought to clarify for decades: whether a surgery conducted since the 1940s benefits the patients ...

Myasthenia gravis usually does not shorten life expectancy, but severe muscle weakness that affects breathing can be life threatening. Myasthenia gravis symptoms may begin suddenly and often progress ...

Francisco J. Rivera Rosario is a science communications editor experienced in developing all types of science content including, scientific journal articles, infographics, medical educational videos, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nicholas Silvestri ...